| HOME >> MEDICINE >> TECHNOLOGY |
"These data show that in this elderly patient population, MP-T therapy offers clear superiority in extending overall survival compared with MP alone," said Dr. Cyrille Hulin, MD, on behalf of the Intergroupe Francophone du Myelome and a principal investigator of the trial. "In a patient population with a median age of nearly 80 years old, a survival advantage of this magnitude is remarkable. MP-T therapy should become the reference treatment for all elderly patients with newly diagnosed multiple myeloma."
Pharmion has submitted an application with the European Medicines Agency (EMEA) for approval of Thalidomide Pharmion as a first line therapy for multiple myeloma in Europe.
Data Presented Saturday, June 2
An analysis of erythropoietin (EPO) and VTE in MM patients treated with anthracycline-based chemotherapy and the immunomodulatory agent thalidomide -- R. Baz; Abstract #8107; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S HallA2
Data Presented Sunday, June 3
Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15 pm; McCormick Place Convention Center, E354b
Oral Presentation: Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM) -- P. Sonneveld; Abstract #8023; June 3, 2007; 3:00-3:15 pm; McCormick Place Convention Center, E354b
A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform -- J. Deeken, MD; Abstract #3580; June 3, 2007; 8:00- 12:00pm; McCormick Place Convention Center, S Hall A2
A Phase II trial of thalidomide, bevacizumab, and docetaxel in
patien
'"/>